AVIDITY BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.64 USD | -6.67% |
|
-3.38% | +206.63% |
Financials (USD)
| Sales 2024 * | 14.77M | Sales 2025 * | 12.14M | Capitalization | 2.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -292M | Net income 2025 * | -326M | EV / Sales 2024 * | 192 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 233 x |
| P/E ratio 2024 * |
-9.21
x | P/E ratio 2025 * |
-8.7
x | Employees | 253 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avidity Biosciences, Inc.
More recommendations
More press releases
| 1 day | -2.90% | ||
| 1 week | +0.38% | ||
| Current month | +19.48% | ||
| 1 month | +14.68% | ||
| 3 months | +105.34% | ||
| 6 months | +360.54% | ||
| Current year | +218.56% |
1 week
28.41
30.84
1 month
23.3530.84
Current year
8.8630.84
1 year
4.8330.84
3 years
4.8330.84
5 years
4.8337.46
10 years
4.8337.46
| Managers | Title | Age | Since |
|---|---|---|---|
Troy Wilson
FOU | Founder | 55 | 12-11-12 |
Sarah Boyce
CEO | Chief Executive Officer | 52 | 19-09-30 |
Michael MacLean
DFI | Director of Finance/CFO | 58 | 20-05-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 13-09-30 |
Carsten Boess
BRD | Director/Board Member | 57 | 20-04-12 |
Edward Kaye
BRD | Director/Board Member | 75 | 19-08-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - | |
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 27.78 | -6.21% | 897 853 |
| 24-05-22 | 29.62 | +0.37% | 921,321 |
| 24-05-21 | 29.51 | +0.92% | 724,718 |
| 24-05-20 | 29.24 | -0.88% | 1,271,039 |
| 24-05-17 | 29.5 | +2.72% | 895,645 |
Delayed Quote Nasdaq, May 23, 2024 at 11:22 am EDT
More quotes
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
29.62
USD
Average target price
45.25
USD
Spread / Average Target
+52.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +218.56% | 2.83B | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| -15.14% | 32.79B | |
| +64.13% | 26.23B | |
| -21.98% | 14.52B | |
| -7.82% | 13.09B | |
| -42.60% | 11.6B | |
| -12.64% | 11.5B | |
| +5.17% | 8.82B |
- Stock Market
- Equities
- RNA Stock
